About sofosbuvir + ledipasvir
Direct-acting antiviral combination
Used for
- Treats chronic hepatitis C in adults and children aged 3 years and older.
- Used for hepatitis C genotypes 1, 4, 5, and 6, with regimen depending on patient factors.
Usual adult dose
One tablet by mouth once daily; treatment usually lasts 8–24 weeks, depending on circumstances.
Usual dose in children
For ages 3 years and older, once daily; dose is weight-based and may use tablets or pellets.
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Important warnings
- Hepatitis B may reactivate during treatment; screening and monitoring are important.
- Do not use with amiodarone unless closely managed; serious slow heart rate can occur.
- Ribavirin-containing treatment can cause serious birth defects and is unsafe during pregnancy.
- Liver function and treatment suitability depend on medical history and other medicines.
Pregnancy
Harvoni alone has limited pregnancy data. Ribavirin combination treatment is contraindicated during pregnancy.
Breastfeeding
It is not known whether these medicines pass into breast milk; discuss risks with a clinician.
Interactions
- Amiodarone: risk of dangerously slow heart rate.
- Rifampin, rifabutin, and rifapentine may reduce antiviral effectiveness.
- St. John’s wort can reduce effectiveness.
- Some antacids and acid-reducing medicines lower ledipasvir absorption.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.